Caribou Biosciences (CRBU) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pelthos Therapeutics (PTHS) has outperformed Caribou Biosciences (CRBU) over the past year, losing 24.5% versus a loss of 82.0%. Pelthos Therapeutics is the larger company by market cap ($78.5 million vs $51.6 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBU | PTHS |
|---|---|---|
| Share price | $0.4812 | $20.50 |
| Market cap | $51.59M | $78.48M |
| 1-day change | -22.06% | -2.33% |
| YTD return | -69.74% | -33.87% |
| 1-year return | -82.04% | -24.47% |
| 5-year return | -97.69% | — |
| EPS (TTM) | $-1.08 | $-27.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $37.50 |
| 52-week low | $0.45 | $18.19 |
| Distance from 52-week high | -86.39% | -45.33% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +1094.93% | +159.22% |
| Average volume | 2.14M | 60.07K |
| Shares outstanding | 107.21M | 3.83M |
| Employees | 97 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTHS has outperformed CRBU by 57.6 percentage points over the past year.
About Caribou Biosciences
CRBU stock →Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 97 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
CRBU vs PTHS FAQ
Which is bigger, Caribou Biosciences or Pelthos Therapeutics?
Pelthos Therapeutics (PTHS) is larger, with a market capitalization of $78.48M compared with $51.59M for Caribou Biosciences (CRBU).
Which stock has performed better over the past year, CRBU or PTHS?
PTHS returned -24.47% over the past 12 months, compared with -82.04% for CRBU (price return, excluding dividends). Past performance does not predict future results.
Are Caribou Biosciences and Pelthos Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.